The Worldwide Market for Liquid Biopsy, 7th Edition

Liquid biopsies have transformed cancer diagnostics by offering a minimally invasive method to analyze tumor-derived materials circulating in biological fluids. This approach provides critical insights for cancer detection, therapy selection, and disease monitoring, complementing or replacing traditional tissue biopsies and imaging techniques that often carry procedural risks and limitations.

Kalorama Information’s The Worldwide Market for Liquid Biopsy, 7th Edition explores the full spectrum of clinical applications driving adoption, including early detection and screening, alternative testing when tissue biopsy is impractical, therapy personalization and monitoring for resistance, disease surveillance for progression and recurrence, and prognostic assessment.

Comprehensive Market Analysis

The Worldwide Market for Liquid Biopsy, 7th Edition delivers a detailed forecast of global liquid biopsy revenues from 2025 to 2030, segmented by:

• Geographic Region: North America, Europe, Asia, and Rest of World, with regional market shares and growth trends.
• Technology Type: Circulating Tumor DNA (ctDNA)-based, Circulating Tumor Cell (CTC)-based, Extracellular Vesicle and Exosome-based, Multi-Analyte-based, and other analyte-driven approaches, including comparative tables of advantages and limitations.
• Cancer Type: Breast, Lung, Colorectal, Ovarian, Prostate, Pan-Cancer, and Other Cancers, with revenue forecasts and share analysis for each indication.
• Application: Diagnosis and Screening, Therapy Guidance, Minimal Residual Disease (MRD), and Disease Prognosis, supported by market sizing and growth projections.

Industry Insights and Competitive Landscape

The report profiles selected liquid biopsy tests currently available and in development, including ctDNA-based assays, CTC-based platforms, and multi-analyte solutions. It examines clinical versus research use and regulatory trends. Detailed chapters cover technology comparisons, analyte-specific market dynamics, and application-level opportunities, supported by over a dozen tables and figures illustrating revenue forecasts, market shares, and growth drivers.

Scope and Methodology

This report covers the global market for liquid biopsy testing. The market data pertains to global and regional revenues at the level of testing companies. This differs from most KI reports, which provide estimates at the level of IVD products. While systems and kits are not excluded, they were not the primary focus of this report. Most companies offer these tests as services.

The base year for data is 2025, with forecasts provided through 2030. Compound annual growth rates (CAGRs) are included for each segment.

Information and data on the global liquid biopsy market were obtained from a wide range of primary and secondary sources. Interviews were conducted with manufacturers of IVD products, clinical laboratory technicians, and other industry experts. Secondary sources included statistical and informational reports and articles from government agencies, trade associations, and independent publishing firms. Annual reports, public filings, and websites of leading companies were also reviewed to identify evolving product and market trends, assess competitive factors, and support the overall industry analysis. Selected Kalorama Information and Strategic Directions International (SDi) publications were also consulted for additional background and context. SDi is Kalorama Information’s sister publishing brand with the Science and Medicine Group.

Please Note: Single user allows for up to 3 users for this report. Show more